Cargando…

Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, synovial hyperplasia, mononuclear cell infiltration, bone erosion and joint destruction. Efficacy of personalized therapy in RA is associated with correct choice of therapeutic agent and a possibility to predict its e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tchetina, Elena V., Markova, Galina A., Satybaldyev, Azamat M., Lila, Aleksandr M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164049/
https://www.ncbi.nlm.nih.gov/pubmed/35678661
http://dx.doi.org/10.3390/cimb44050132
_version_ 1784720052142997504
author Tchetina, Elena V.
Markova, Galina A.
Satybaldyev, Azamat M.
Lila, Aleksandr M.
author_facet Tchetina, Elena V.
Markova, Galina A.
Satybaldyev, Azamat M.
Lila, Aleksandr M.
author_sort Tchetina, Elena V.
collection PubMed
description Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, synovial hyperplasia, mononuclear cell infiltration, bone erosion and joint destruction. Efficacy of personalized therapy in RA is associated with correct choice of therapeutic agent and a possibility to predict its effect prior to treatment. Our objective was to examine the association of baseline expression of metalloproteinase (MMP)-9 and cathepsin K, which are involved in cartilage and bone degradation, as well as proinflammatory cytokines tumour necrosis factor (TNF)α and interleukin (IL)-1β in the peripheral blood mononuclear cells (PBMCs) obtained from patients with RA cultured with tofacitinib (TFCN) and remission achievement. We examined 12 tofacitinib-naïve patients with RA, with a median age of 51 years and disease duration of 37.6 months. After three months of TFCN therapy, six of these patients reached clinical remission criteria while others preserved high and moderate disease activity. PBMCs were tested prior to therapy followed by their isolation in Ficoll density gradient and cultured with 100 nM TFCN for 48 h. Gene expression analysis for MMP-9, cathepsin K, IL-1β, and TNFα was performed with quantitative real-time RT-PCR using total RNA isolated from and cultured with TFCN PBMCs compared with untreated cells. Expression of all the examined genes was significantly upregulated in those cultured with TFCN PBMCs from patients who maintained high and moderate disease activity after TFCN therapy while TNFα gene expression was significantly downregulated in patients who gained remission compared with untreated counterparts. Downregulation of TNFα gene expression in PBMCs from TFCN-naïve patients with RA cultured with TFCN prior to therapy compared with untreated counterparts might serve a prognostic biomarker for remission attainment in response to tofacitinib therapy.
format Online
Article
Text
id pubmed-9164049
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91640492022-06-04 Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Tchetina, Elena V. Markova, Galina A. Satybaldyev, Azamat M. Lila, Aleksandr M. Curr Issues Mol Biol Communication Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, synovial hyperplasia, mononuclear cell infiltration, bone erosion and joint destruction. Efficacy of personalized therapy in RA is associated with correct choice of therapeutic agent and a possibility to predict its effect prior to treatment. Our objective was to examine the association of baseline expression of metalloproteinase (MMP)-9 and cathepsin K, which are involved in cartilage and bone degradation, as well as proinflammatory cytokines tumour necrosis factor (TNF)α and interleukin (IL)-1β in the peripheral blood mononuclear cells (PBMCs) obtained from patients with RA cultured with tofacitinib (TFCN) and remission achievement. We examined 12 tofacitinib-naïve patients with RA, with a median age of 51 years and disease duration of 37.6 months. After three months of TFCN therapy, six of these patients reached clinical remission criteria while others preserved high and moderate disease activity. PBMCs were tested prior to therapy followed by their isolation in Ficoll density gradient and cultured with 100 nM TFCN for 48 h. Gene expression analysis for MMP-9, cathepsin K, IL-1β, and TNFα was performed with quantitative real-time RT-PCR using total RNA isolated from and cultured with TFCN PBMCs compared with untreated cells. Expression of all the examined genes was significantly upregulated in those cultured with TFCN PBMCs from patients who maintained high and moderate disease activity after TFCN therapy while TNFα gene expression was significantly downregulated in patients who gained remission compared with untreated counterparts. Downregulation of TNFα gene expression in PBMCs from TFCN-naïve patients with RA cultured with TFCN prior to therapy compared with untreated counterparts might serve a prognostic biomarker for remission attainment in response to tofacitinib therapy. MDPI 2022-04-29 /pmc/articles/PMC9164049/ /pubmed/35678661 http://dx.doi.org/10.3390/cimb44050132 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Tchetina, Elena V.
Markova, Galina A.
Satybaldyev, Azamat M.
Lila, Aleksandr M.
Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title_full Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title_fullStr Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title_full_unstemmed Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title_short Downregulation of Tumour Necrosis Factor α Gene Expression in Peripheral Blood Mononuclear Cells Cultured in the Presence of Tofacitinib Prior to Therapy Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis
title_sort downregulation of tumour necrosis factor α gene expression in peripheral blood mononuclear cells cultured in the presence of tofacitinib prior to therapy is associated with clinical remission in patients with rheumatoid arthritis
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164049/
https://www.ncbi.nlm.nih.gov/pubmed/35678661
http://dx.doi.org/10.3390/cimb44050132
work_keys_str_mv AT tchetinaelenav downregulationoftumournecrosisfactorageneexpressioninperipheralbloodmononuclearcellsculturedinthepresenceoftofacitinibpriortotherapyisassociatedwithclinicalremissioninpatientswithrheumatoidarthritis
AT markovagalinaa downregulationoftumournecrosisfactorageneexpressioninperipheralbloodmononuclearcellsculturedinthepresenceoftofacitinibpriortotherapyisassociatedwithclinicalremissioninpatientswithrheumatoidarthritis
AT satybaldyevazamatm downregulationoftumournecrosisfactorageneexpressioninperipheralbloodmononuclearcellsculturedinthepresenceoftofacitinibpriortotherapyisassociatedwithclinicalremissioninpatientswithrheumatoidarthritis
AT lilaaleksandrm downregulationoftumournecrosisfactorageneexpressioninperipheralbloodmononuclearcellsculturedinthepresenceoftofacitinibpriortotherapyisassociatedwithclinicalremissioninpatientswithrheumatoidarthritis